🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The fight against malaria has been marked by numerous highs and lows, but our commitment to eliminate the disease remains unwavering. We need to act now to make malaria a problem of the past. #WHA77 #EndMalaria #Malaria Harvard T.H. Chan School of Public Health RBM Partnership

It was a pleasure to join leaders of our LGBTQI community and so many more Cambridge colleagues for this year’s Pride flag-raising event. Thank you to all who attended to celebrate equity, inclusion, dignity, and visibility to kick off #PrideMonth this year.

Excited to see this published in Science Magazine—our team’s paper on the discovery of molecular glue degraders to induce fetal hemoglobin—a potential avenue toward creating an accessible oral therapy for #sicklecelldisease. Congrats to Pamela Ting, Jay Bradner, M.D. and all involved

This is an exciting opportunity to learn from brilliant mentors while applying your AI and #datascience skills in the field of drug discovery. Recent PhD graduates are encouraged to apply by July 29. linkedin.com/posts/novartis…

I had a wonderful visit to our San Diego Biomedical Research hub where I met with many of our remarkable scientists, including contributors to this ingenious technology. Exciting to see the work spark valuable insights in the hunt for new heart disease drugs.

I’m pleased to share that Novartis has entered into a collaboration agreement with Dren Bio to discover and advance novel antibody-based immune cell engagers for certain cancers. businesswire.com/news/home/2024…

This exciting news from the FDA brings a new treatment option to the US for reduction of proteinuria in certain adults with IgA nephropathy. Congratulations to all who helped achieve this milestone, including the many patients and clinicians who participated in clinical trials.

So glad I could be present to celebrate this milestone. FMI science is a research powerhouse. I have no doubt this amazing new facility will be the home of many transformativediscoveries in the coming years.

I’m excited to share that Novartis and Generate:Biomedicines will collaborate to apply generative #AI to the discovery of next-gen biologics -- another example of our commitment to leveraging promising AI tools to help accelerate #drugdiscovery and development businesswire.com/news/home/2024…

Delighted to see our Isomorphic Labs collaborator Demis Hassabis, along with John Jumper and David Baker, awarded the Nobel Prize in Chemistry for computational approaches to protein prediction & design—brilliant work with the potential to transform drug discovery. Congrats, all!

Congrats to our Global Health research team, who describe the discovery of a preclinical, GI-targeted oral molecule for the potential treatment of pediatric cryptosporidiosis in Nature Microbiology. nature.com/articles/s4156…

It was a pleasure to speak with C&EN about AlphaFold and the Nobel Prize-winning tech powering next-gen structure-based drug design—including our work with Demis Hassabis Isomorphic Labs, using #AI to accelerate the drug discovery process cen.acs.org/people/nobel-p…

I’m happy to share that Novartis and Monte Rosa Therapeutics, Inc have announced an exclusive global development and commercialization license agreement to advance molecular glue degraders. ir.monterosatx.com/news-releases/…

Excited to share that the FDA has approved our medicine as a first-line treatment for adults with Ph+ CML in chronic phase – a testament to our researchers’ commitment to innovating new therapies to address unmet needs of cancer patients. novartis.com/news/media-rel…

I’m excited to share that we've entered into a research collaboration and expanded software licensing agreement with Schrödinger, combining our research capabilities with Schrödinger’s computational chemistry tools to enhance our drug discovery efforts. fiercebiotech.com/biotech/novart…

Very happy to share that Novartis is collaborating with Ratio Therapeutics to advance a next-generation RLT candidate, and bring forward additional therapeutic options for patients with difficult to treat cancer. ratiotx.com/2024/11/18/nov…

I’m happy to share that we’ve entered into a strategic collaboration with Vyriad to discover and develop in vivo CAR-T cell therapies to expand the potential of CAR-Ts to benefit a broader range of patients. vyriad.com/newsevents/vyr…

Pleased to share that Novartis has acquired Kate Therapeutics. This is an exciting deal that will add to our expertise and capabilities to help us advance novel gene therapies with transformative potential for people with inherited neuromuscular diseases. novartis.com/stories/addres…

Thank you to Google DeepMind and The Royal Society for inviting me to take part in the AI for Science Forum—and to fellow panelists Eric Topol, Alison Noble, and Pushmeet Kohli for the insightful discussion on the transformative potential and impact of #AI on scientific discovery.

I’m pleased to share that Novartis has entered a collaboration with BioAge aimed at discovering novel targets for potential therapies for age-related diseases. We look forward to the groundbreaking discoveries that this collaboration could bring. ir.bioagelabs.com/news-releases/…